HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 350.70% from the company’s current price.

Separately, StockNews.com lowered shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Trading Up 13.4 %

ACIU stock opened at $3.55 on Friday. The stock has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $3.47. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its position in AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after purchasing an additional 7,400 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of AC Immune during the 2nd quarter worth about $218,000. Renaissance Technologies LLC boosted its holdings in shares of AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after buying an additional 136,300 shares during the period. Vanguard Capital Wealth Advisors acquired a new position in AC Immune in the 2nd quarter valued at about $56,000. Finally, Assenagon Asset Management S.A. grew its stake in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after buying an additional 328,312 shares during the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.